Fractalkine in rheumatoid arthritis: A review to date

38Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rheumatoid arthritis (RA) is characterized by the expansion of the synovium, with infiltration of pro-inflammatory cells, neovascularization and an abundance of pro-inflammatory cytokines resulting in tissue destruction and bone erosion. Fractalkine (FKN), a recently described chemokine, possesses chemotactic, angiogenic and adhesive functions that associates it with all of these destructive processes. In this review, we describe the research to date, which implicates FKN and its receptor in the pathogenesis of RA and propose that this molecule may represent a future therapeutic target for RA. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

Cite

CITATION STYLE

APA

Murphy, G., Caplice, N., & Molloy, M. (2008). Fractalkine in rheumatoid arthritis: A review to date. Rheumatology. https://doi.org/10.1093/rheumatology/ken197

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free